HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues. A review of their pharmacology and clinical potential in the treatment of viral infections

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 1, 1997, Pages 1-23

  Naesens, L ^a   Snoeck, R ^a   Andrei, G ^a   Balzarini, J ^a   Neyts, J ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Acyclic nucleoside phosphonates; HPMPC (cidofovir); PMEA (adefovir); PMPA

Indexed keywords

2,6 DIAMINO 9 (2 PHOSPHONOMETHOXYETHYL)PURINE; 9 (3 FLUORO 2 PHOSPHONOMETHOXYPROPYL)ADENINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ACYCLIC NUCLEOSIDE; ACYCLIC NUCLEOSIDE PHOSPHONATE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; DRUG METABOLITE; FOSCARNET; GANCICLOVIR; PROBENECID; PRODRUG; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS ENZYME; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DNA VIRUS; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; HEPATITIS B VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; RETROVIRUS; REVIEW; TOPICAL DRUG ADMINISTRATION; VIRUS INFECTION;

EID: 0031036704     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800101     Document Type: Review

References (147)

1. Aduma PP, Connelly MC, Srinivas RV & Fridland A (1995) Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Molecular Pharmacology 47:816-822.
2. Andrei G, Snoeck R, Schols D, Goubau P, Desmyter J & De Clercq E (1991) Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. European Journal of Clinical Microbiology and Infectious Diseases 10:1026-1033.
3. Andrei G, Snoeck R, Goubau P, Desmyter J & De Clercq E (1992) Comparative activity of various compounds against clinical strains of herpes simplex virus. European Journal of Clinical Microbiology and Infectious Diseases 11:143-151.
4. Andrei G, Snoeck R & De Clercq E (1995a) Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Antimicrobial Agents and Chemotherapy 39:1632-1635.
5. Andrei G, Snoeck R, Reymen D, Liesnard C, Goubau P, Desmyter J & De Clercq E (1995b) Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. European Journal of Clinical Microbiology and Infectious Diseases 14:318-328.
6. Andrei G, Snoeck R, Vandeputte M & De Clercq E (1996a) Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC, cidofovir) against murine and human polyomavirus replication in vitro. Antiviral Research 30:A55.
7. Andrei G, Snoeck R, Vandeputte M & De Clercq E (1996b) Antiviral activity of various compounds against murine, simian and primate polyomaviruses. Antimicrobial Agents and Chemotherapy (in press).
8. Awan AR & Field HJ (1993) Effects of phosphonylmethoxyalkyl derivatives studied with a murine model for abortion induced by equine herpesvirus 1. Antimicrobial Agents and Chemotherapy 37:2478-2482.
9. Baba M, Mori S, Shigeta S & De Clercq E (1987a) Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrobial Agents and Chemotherapy 31:337-339.
10. Baba M, Konno K, Shigeta S & De Clercq E (1987b) in vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-adenine against newly isolated clinical varicella-zoster virus strains. European Journal of Clinical Microbiology 6:158-160.
11. Balzarini J (1994) Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharmacy World and Science 16:113-126.
12. Balzarini J & De Clercq E (1991) 5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. Journal of Biological Chemistry 266:8686-8689.
13. Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holý A, Pauwels R, Baba M, Johns DG & De Clercq E (1989) Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)-adenine, a selective anti-human immunodeficiency virus agent. Proceedings of the National Academy of Sciences, USA 86:332-336.
14. Balzarini J, Naesens L & De Clercq E (1990a) Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. International Journal of Cancer 46:337-340.
15. Balzarini J, Sobis H, Naesens L, Vandeputte M & De Clercq E (1990b) Inhibitory effects of 9-(2-phosphonylmethoxyethyl)-adenine and 3′-azido-2′,3′-dideoxy-thymidine on tumor development in mice inoculated intracerebrally with Moloney murine sarcoma virus. International Journal of Cancer 45:486-489.
16. Balzarini J, Hao Z, Herdewijn P, Johns DG & De Clercq E (1991a) Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proceedings of the National Academy of Sciences, USA 88:1499-1503.
17. Balzarini J, Holý A, Jindřich J, Dvořáková H, Hao Z, Snoeck R, Herdewijn P, Johns DG & De Clercq E (1991b) 9-[(2RS)-3-Fluoro-2-phosphonylmethoxypropyl]derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proceedings of the National Academy of Sciences, USA 88:4961-4965.
18. Balzarini J, Naesens L, Slachmuylders J, Niphuis H, Rosenberg I, Holý A, Schellekens H & De Clercq E (1991c) 9-(2-Phosphonyl-methoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys, AIDS 5:21-28.
19. Balzarini J, Holý A, Jindrich J, Naesens L, Snoeck R, Schols D & De Clercq E (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphorates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethaxypropyl)-2,6-diaminopurine. Antimicrobial Agents and Chemotherapy 37:332-338.
20. Balzarini J, Navé J-F, Becker MA, Tatibana M & De Clercq E (1995) Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver and human erythrocytes. Nucleosides and Nucleotides 14:1861-1871.
21. Balzarin, J, Aquaro S, Perno C-F, Witvrouw M, Holý A & De Clercq E (1996) Activity of the (R)-enantiomers of 9-(2-phosphonyl-methoxypropyl)adenine and 9-(2-phosphonyl-methoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochemical and Biophysical Research Communications 219:337-341.
22. Barditch-Crovo PA, Toole J, Burgee H, Wachsman M, Ebeling D, Cundy KC, Jaffe HS & Lietman PS (1995) A randomized double-blind, placebo-controlled Phase I/II evaluation of 9-[2-(bispivaloyloxymethyl)phosphonylmethoxyethyl]adenine (bis-POM PMEA), an orally bioavailable prodrug of the anti-HIV nucleotide, PMEA. Abstracts of the 8th International Conference on Antiviral Research, Santa Fe New Mexico, USA, April 23-28 1995. Antiviral Research 26:A229.
23. Besen G, Flores-Aguilar M, Assil KK, Kupperman BD, Gangan P, Pursley M, Munguia D, Vuong C, De Clercq E, Bergeron-Lynn G Azen SP & Freeman WR (1995) Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. Archives of Ophthalmology 113:661-668.
24. Bischofberger N, Hitchcock MJM, Chen MS Barkhimer DB Cundy KC, Kent KM, Lacy SA, Lee WA, Li Z-H, Mendel DB Smee DF & Smith JL (1994) 1-[(S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine with improved therapeutic index in vivo. Antimicrobial Agents and Chemotherapy 38:2387-2391.
25. Bischofberger N, Tsai C-C, Follis KE, Sabo A, Grant RF, Beck TW, Dalley PJ & Black R (1996) Antiviral efficacy of PMPA in macaques chronically infected with SIV. Abstracts of the 9th International Conference on Antiviral Research, Urabandai, Fukushima, Japan, May 19-24 1996. Antiviral Research 30:A42.
26. Bravo FJ, Stanberry LR, Kier AB, Vogt PE & Kern ER (1993) Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Research 21:59-72.
27. Bronson JJ, Ghazzouli I, Hitchcock MJM, Webb RR & Martin IC (1989) Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine. Journal of Medicinal Chemistry 32:1457-1463.
28. Caliò R, Villani N, Balestra E, Sesa F, Holý A, Balzarini J, De Clercq E, Perno C-F & Del Gobbo V (1994) Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Research 23:77-89.
29. Černv J, Votruba I, Vonka V, Rosenberg I, Otmar M & Holý A (1990) Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase. Antiviral Research 13:253-264.
30. Cherrington JM, Allen SJ, McKee BH & Chen MS (1994) Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP & FIAUTP with human DNA polymerases β and γ. Biochemical Pharmacology 48:1986-1988.
31. Cherrington JM, Allen SJW, Bischofberger N & Chen MS (1995) Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human polymerases α, β and γ. Antiviral Chemistry & Chemotherapy 6:217-221.
32. Cherrington JM, Mulato AS, Fuller MD & Chen MS (1996) Novel mutation (K7OE) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonylmethoxy)ethyl]adenine in vitro. Antimicrobial Agents and Chemotherapy 40:2212-2216.
33. Cihlář T & Chen MS (1997) Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Molecular Pharmacology (in press).
34. Cihlář T, Votruba I, Horská K, Liboska R, Rosenberg I & Holý A (1992) Metabolism of 1-(S)-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine (HPMPC) in human embryonic lung cells. Collection of Czechoslovak Chemical Communications 57:661-672.
35. Cihlář T, Rosenberg I, Votruba I & Holý A (1995) Transport of 9-(2-phosphonomethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated. Antimicrobial Agents and Chemotherapy 39:117-124.
36. Connelly MC, Robbins BL & Fridland A (1993) Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochemical Pharmacology 46:1053-1057.
37. Cundy KC, Fishback JA, Shaw J-P, Lee ML, Soike KF, Visor GC & Lee WA (1994a) Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis (pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharmaceutical Research 11:839-843.
38. Cundy KC, Li Z-H & Lee WA (1994b) Effect of concomitant probenecid on the tissue distribution and urinary excretion of HPMPC in preclinical models. Pharmaceutical Research 11(Suppl.):S-449.
39. Cundy KC, Shaw J-P & Lee WA (1994c) Oral, subcutaneous and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine in cynomolgus monkeys. Antimicrobial Agents and Chemotherapy 38:365-368.
40. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJM & Jaffe HS (1995a) Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 39:1247-1252.
41. Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J & Jaffe HS (1995b) Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents and Chemotherapy 39:2401-2405.
42. Cundy KC, Li Z-H, Hitchcock MJM & Lee WA (1996a) Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metabolism and Disposition 24:738-744.
43. Cundy KC, Bidgood AM, Lynch G, Shaw J-P, Griffin L & Lee WA (1996b) Pharmacokinetics, bioavailability, metabolism and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metabolism and Disposition 24:745-752.
44. Darby G & Field HJ (1981) Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature 289:81-83.
45. De Castro LM, Kern ER, De Clercq E, Ghaffar A, Mayer EP, Vogt PE & Gangemi JD (1991) Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Research 16:101-114.
46. De Clercq E (1991) Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochemical Pharmacology 42:963-972.
47. De Clercq E, & Holý A (1991) Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrobial Agents and Chemotherapy 35:701-706.
48. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J & Maudgal PC (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467.
49. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I & Holý A (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Research 8:261-272.
50. De Clercq E, Holý A & Rosenberg I (1989) Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrobial Agents and Chemotherapy 33:185-191.
51. Del Gobbo V, Foli A, Balzarini J, De Clercq E, Balestra E, Villani N, Marini S, Perno C-F & Caliò R (1991) Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleoside analogue, on in vivo murine models. Antiviral Research 16:65-75.
52. De Oliveira CBR, Stevenson D, LaBree L, McDonnell PJ & Trousdale MD (1996) Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Research 31:165-172.
53. Egberink H, Borst M, Niphuis H, Balzarini J, Neu H, Schellekens H, De Clercq E, Horzinek M & Koolen M (1990) Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proceedings of the National Academy of Sciences, USA 87:3087-3091.
54. Fazely F, Haseltine WA, Rodger RF & Ruprecht RM (1991) Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-α: failure after inoculating rhesus monkeys with a high dose of SIV. Journal of Acquired Immune Deficiency Syndromes 4:1093-1097.
55. Field HJ (1989) Persistent herpes simplex virus infections and mechanisms of virus drug resistance. European Journal of Clinical Microbiology and Infectious Diseases 8:671-680.
56. Field HJ & Awan AR (1990) Effective chemotherapy of equine herpesvirus 1 by phosphonylmethoxyalkyl derivatives of adenine demonstrated in a novel murine model for the disease. Antimicrobial Agents and Chemotherapy 34:709-717.
57. Flores-Aguilar M, Huang J-S, Wiley CA, De Clercq E, Vuong C, Bergeron-Lynn G, Chandler B, Munguia D, Dolnak DR & Freeman WR (1994) Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. Journal of Infectious Diseases 169:642-647.
58. Foli A, Sopocio M, Anderson B, Kavlick M, Saville MW, Wainberg MA, Gu Z, Cherrington JM, Mitsuya H & Yarchoan R (1996). In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonylmethoxy)ethyl]adenine (PMEA). Antiviral Research 32:91-98.
59. Gangemi JD, Cozens RM, De Clercq E, Balzarini J & Hochkeppel H-K (1989) 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrobial Agents and Chemotherapy 33:1864-1868.
60. Gil-Fernández C & De Clercq E (1987) Comparative efficacy of broad-spectrum antiviral agents as inhibitors of African swine fever virus replication in vitro. Antiviral Research 7:151-160.
61. Gil-Fernández C, García-Villalón D, De Clercq E, Rosenberg I & Holý A (1987) Phosphonylmethoxyalkylpurines and -pyrimidines as inhibitors of African swine fever virus replication in vitro. Antiviral Research 8:273-282.
62. Gilliam SE & Field HJ (1993) The effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) on bovine herpesvirus-1 (BHV-1) infection and reactivation in cattle. Antiviral Research 20:21-32.
63. Gong Y-F, Marshall DR, Srinivas RV & Fridland A (1994) Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrobial Agents and Chemotherapy 38:1683-1687.
64. Gordon YJ, Romanowski E, Araullo-Cruz T, Seaberg L, Erzurum S, Tolman R & De Clercq E (1991) Inhibitory effect of (S)-HPMPC, (S)-HPMPA and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Research 16:11-16.
65. Gordon YJ, Romanowski EG & Araullo-Cruz T (1994) Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Investigative Ophthalmology and Visual Science 35:4135-4143.
66. Gordon YJ, Naesens L, De Clercq E, Maudgal PC & Veckeneer M (1996) Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea 15:546.
67. Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM & Wainberg MA (1995) K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrobial Agents and Chemotherapy 39:1888-1891.
68. Hartmann K, Donath A, Beer B, Egberink HF, Horzinek MC, Lutz H, Hoffmann-Fezer G, Thum I & Thefeld S (1992) Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Veterinary Immunology and Immunopathology 35:167-175.
69. Hartmann K, Balzarini J, Higgins J, De Clercq E & Pedersen NC (1994) In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandell feline kidney cells and feline peripheral blood lymphocytes. Antiviral Chemistry & Chemotherapy 5:13-19.
70. Heijtink RA, De, Wilde GA, Kruining J, Berk L, Balzarini J, De Clercq E, Holý A & Schalm SW (1993) Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Research 21:141-153.
71. Heijtink RA, Kruining J, De Wilde GA, Balzarini J, De Clercq E & Schalm SW (1994) Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrobial Agents and Chemotherapy 38:2180-2182.
72. Hitchcock MJM, Jaffe HS, Martin JC & Stagg RJ (1996) Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chemistry & Chemotherapy 7:115-127.
73. Ho H-T, Woods KL, Bronson JJ, De Boeck H, Martin JC & Hitchcock MJM (1992) Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine. Molecular Pharmacology 41:197-202.
74. Holý A & Rosenberg I (1987) Synthesis of 9-(2-phosphonyĺ methoxyethyl)adenine and related compounds. Collection of Czechoslovak Chemical Communications 52:2801-2809.
75. Holý A, Votruba I, Merta A, Černy J, Vesely J, Vlach J, Šedivá K, Rosenberg I, Otmar M, Hřebabecký H, Trávníček M, Vonka V, Snoeck R & De Clercq E (1990) Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Research 13:295-312.
76. Hoover EA, Ebner JP, Zeidner NS & Mullins JI (1991) Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Antiviral Research 16:77-92.
77. Kim CU, Luh BY, Misco PF, Bronson JJ, Hitchcock MJM, Ghazzouli I & Martin JC (1989) Synthesis and biological activities of phosphonylalkylpurine derivatives. Nucleosides and Nucleotides 8:927-931.
78. Kirsch LS, Arevalo JF, De Clercq E, Chavez E, Munguia D, Garcia R & Freeman WR (1995a) Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. American Journal of Ophthalmology 119:466-476.
79. Kirsch LS, Arevalo JF, Chavez E, Munguia D, De Clercq E & Freeman WR (1995b) Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 102:533-542.
80. Kramata P, Votruba I, Otová B & Holý A (1996) Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases α, δ & ε. Molecular Pharmacology 49:1005-1011.
81. Kupperman BD, Assil KK, Vuong C, Besen G, Wiley CA, De Clercq E, Bergeron-Lynn G, Connor JD, Pursley M, Munguia D & Freeman WR (1996) Liposome-encapsulated (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine for long-acting therapy of viral retinitis. Journal of 'Infectious Diseases 173:18-23.
82. Lalezari JP, Drew WL, Glutzer E, Miner D, Safrin S, Owen WF, Davidson JM, Fisher PE & Jaffe HS (1994) Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxypropyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. Journal of Infectious Diseases 170:570-572.
83. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC & Jaffe HS (1995) (S)-1-[3-Hydroxy-2-phosphonyl-methoxy)propyl]-cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. Journal of Infectious Diseases 171:788-796.
84. Lalezari JP, Stagg R, Kuppermann B, Holland G, Kramer F, Youle M, Robinson M, Northfelt D, Eron J & Jaffe HS (1996) A randomized, controlled trial of cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Annals of Internal Medicine (in press).
85. Lee JS, Mullaney S, Bronson R, Sharpe AH, Jaenisch R, Balzarini J, De Clercq E & Ruprecht RM (1991) Transplacental antiretroviral therapy with 9-(2-phosphonylmethoxyethyl)adenine is embryotoxic in transgenic mice. Journal of Acquired Immune Deficiency Syndromes 4:833-838.
86. Li SB, Yang ZH, Feng JS, Fong CKY, Lucia HL & Hsiung GD (1990) Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Research 13:237-252.
87. Lin JC, De Clercq E & Pagano JS (1987) Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrobial Agents and Chemotherapy 31:1431-1433.
88. Lin J-C, De Clercq E & Pagano JS (1991) Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrobial Agents and Chemotherapy 35:2440-2443.
89. Littler E, Stuart AD & Chee MS (1992) Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
90. Lurain NS, Spafford LE & Thompson KD (1994) Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. Journal of Virology 68:4427-4431.
91. - HSV-1 keratitis in rabbits. Antiviral Research 16:93-100.
92. Maudgal PC & De Clercq E (1991b) (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis. Investigative Ophthalmology and Visual Science 32:1816-1820.
93. Mendel DB, Barkhimer DB, Kern ER & Chen MS (1995) Isolation and initial characterization of a herpes simplex virus type 2 (HSV-2) strain with decreased sensitivity to cidofovir. Antiviral Research 26:A312.
94. Mendel DB, Cihlář T, Moon K & Chen MS (1996) Cyclic HPMPC (cHPMPC) is hydrolyzed to cidofovir (CDV) by an intracellular cCMP phosphodiesterase. Antiviral Research 30:A49.
95. Merta A, Votruba I, Rosenberg I, Otmar M, Hřebabecký H, Bernaerts R & Holý A (1990) Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Research 13:209-218.
96. Merta A, Votruba I, Jindřich J, Holý A, Cihlář T, Rosenberg I, Otmar M & Herve TY (1992) Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP (dAMP) kinase from L1210 cells. Biochemical Pharmacology 44:2067-2077.
97. Mul YM, van Miltenburg RT, De Clercq E & van der Vliet PC (1989) Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein. Nucleic Acids Research 17:8917-8929.
98. Naesens L, Balzarini J, Rosenberg I, Holý A & De Clercq E (1989) 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. European Journal of Clinical Microbiology and Infectious Diseases 8:1043-1047.
99. Naesens L, Balzarini J, Holý A, Rosenberg I & De Clercq E (1990) Antiretroviral efficacy of 9-(2-phosphonylmethoxyethyl) adenine and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine in mice infected with Friend leukemia virus [Abstract]. Journal of Cellular Biochemistry 14D(Suppl):140.
100. Naesens L, Balzarini J & De Clercq E (1991) Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Research 16:53-64.
101. Naesens L, Balzarini J & De Clercq E (1992) Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. Drug Metabolism and Disposition 20:747-752.
102. Naesens L, Neyts J, Balzarini J, Holý A, Rosenberg I & De Clercq E (1993) Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. Journal of Medical Virology 39:167-172.
103. Naesens L, Balzarini J, Bischofberger N & De Clercq E (1996) Antiretroviral activity and pharmacokinetics in mice of oral bis-(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis (pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxy-ethyl)adenine. Antimicrobial Agents and Chemotherapy 40:22-28.
104. Neyts J, Snoeck R, Schols D, Balzarini J & De Clercq E (1990) Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 179:41-50.
105. Neyts J, Snoeck R, Balzarini J & De Clercq E (1991) Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Research 16:41-52.
106. Neyts J, Balzarini J, Naesens L & De Clercq E (1992) Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. Journal of Medical Virology 37:67-71.
107. Neyts J, Sobis H, Snoeck R, Vandeputte M & De Clercq E (1993a) Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. European Journal of Clinical Microbiology and Infectious Diseases 12:269-279.
108. Neyts J, Stals F, Bruggeman C & De Clercq E (1993b) Activity of the anti-HIV agent 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo. European Journal of Clinical Microbiology and Infectious Diseases 12:437-446.
109. Palú G, Stefanelli S, Rassu M, Parolin C, Balzarini J & De Clercq E (1991) Cellular uptake of phosphonylmethoxyalkyl-purine derivatives. Antiviral Research 16:115-119.
110. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holý A & De Clercq E (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrobial Agents and Chemotherapy 32:1025-1030.
111. Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, Falloon J, Davey RT, Kovacs JA, Walker RE, Whitcup SM, Nussenblatt RB, Lane HC & Masur H (1995) Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrobial Agents and Chemotherapy 39:882-886.
112. Reymen D, Naesens L, Balzarini J, Holý A, Dvořáková H & De Clercq E (1995) Antiviral activity of selected acyclic nucleoside analogues against human herpes virus 6. Antiviral Research 28:343-357.
113. Robbins BL, Connelly MC, Marshall DR, Srinivas RV & Fridland A (1995a) A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Molecular Pharmacology 47:391-397.
114. Robbins BL, Greenhaw J, Connelly MC & Fridland A (1995b) Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) in human lymphoid cells. Antimicrobial Agents and Chemotherapy 39:2304-2308.
115. Sedivá K, Ananiev AV, Votruba I, Holý A & Rosenberg I (1991) Inhibition of purine nucleoside phosphorylase by phosphonylmethoxyalkyl analogues of nucleotides. International Journal of Purine Pyrimidine Research 2:35-39.
116. Smee DF, Morris JLB, Leonhardt JA, Mead JR, Holý A & Sidwell RW (1992) Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine, interferon & bropirimine. Antimicrobial Agents and Chemotherapy 36:1837-1842.
117. Snoeck R, Sakuma T, De Clercq E, Rosenberg I & Holý A (1988) (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy 32:1839-1844.
118. Snoeck R, Andrei G, Gérard M, Silverman A, Hedderman A, Balzarini J, Sadzot-Delvaux C, Tricot G, Clumeck N & De Clercq E (1994) Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clinical Infectious Diseases 18:570-578.
119. Snoeck R, Van Ranst M, Andrei G, De Clercq E, De Wit S, Poncin M & Clumeck N (1995) Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. New England Journal of Medicine 333:943-944.
120. Snoeck R, Andrei G & De Clercq E (1996a) Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. European Journal of Clinical Microbiology and Infectious Diseases 15:574-579.
121. Snoeck R, De Wit S, Rossi C, Dachy B, O'Doherty E, Naesens L, Balzarini J, De Clercq E, Goldman S & Clumeck N (1996b) Treatment of progressive multifocal leukoencephalopathy (PML) with cidofovir in an AIDS patient. Antiviral Research 30:A51.
122. Snoeck R, Wellens W, Desloovere C, Van Ranst M, De Clercq E & Feenstra L (1996c) Treatment of severe recurrent laryngeal papillomatosis by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir). Antiviral Research 30:A25.
123. Soike KF, Huang J-L, Zhang J-Y, Bohm R, Hitchcock MJM & Martin JC (1991) Evaluation of infrequent dosing regimens with (5)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine [(S)-HPMPC] on simian varicella infection in monkeys. Antiviral Research 16:17-28.
124. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM & Ho DD (1996) Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. Journal of Experimental Medicine 183:215-225.
125. Srinivas RV, Robbins BL, Connelly MC, Gong Y-F, Bischofberger N & Fridland A (1993) Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrobial Agents and Chemotherapy 37:2247-2250.
126. Stals FS, De Clercq E & Bruggeman CA (1991) Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. Antimicrobial Agents and Chemotherapy 35:2262-2266.
127. Stals FS, Zeytinoglu A, Havenith M, De Clercq E & Bruggeman CA (1993) Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. Antimicrobial Agents and Chemotherapy 37:218-223.
128. Starrett JE, Tortolani DR, Hitchcock MJM, Martin JC & Mansuri MM
129. Starrett JE, Tortolani DR, Russell J, Hitchcock MJM, Whiterock V, Martin JC & Mansuri MM (1994) Synthesis, oral bioavailability determination and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Journal of Medicinal Chemistry 37:1857-1864.
130. Sullivan V, Biron KK, Talarico C, Stanat SC, Davis M, Pozzi LM & Coen DM (1993) A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrobial Agents and Chemotherapy 37:19-25.
131. Thormar H, Balzarini J, Holý A, Jindřich J, Rosenberg I, Debyser Z, Desmyter J & De Clercq E (1993) Inhibition of visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogs. Antimicrobial Agents and Chemotherapy 37:2540-2544.
132. Thormar H, Balzarini J, Debyser Z, Witvrouw M, Desmyter J & De Clercq E (1995a) Inhibition of visna virus replication and cytopathic effect in sheep choroid plexus cell cultures by selected anti-HIV agents. Antiviral Research 27:49-57.
133. Thormar H, Georgsson G, Pálsson PA, Balzarini J, Naesens L, Torsteinsdóttir S & De Clercq E (1995b) Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs. Proceedings of the National Academy of Sciences, USA 92:3283-3287.
134. Tsai C-C, Follis KE, Sabo A, Grant RF, Bartz C, Nolte RE, Benveniste RE & Bischofberger N (1994a) Pre-exposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against simian immunodeficiency virus infection in macaques. Journal of Infectious Diseases 169:260-266.
135. mne infection in macaques. Journal of Medical Primatology 23:175-183.
136. Tsai C-C, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste RE & Black R (1995a) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)-adenine. Science 270:1197-1199.
137. Tsai C-C, Follis KE, Sabo A, Grant R & Bischofberger N (1995b) Efficacy of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) treatment against chronic simian immunodeficiency virus infection in macaques. Journal of Infectious Diseases 171:1338-1343.
138. Vahlenkamp TW, Deronde A, Balzarini J, Naesens L, De Clercq E, Van Eijk MJT, Horzinek MC & Egberink HF (1995) (A)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 39:746-749.
139. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, Janssens J, Rutgeerts R, Vantrappen G & De Clercq E (1995) Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. Journal of Medical Virology 45:230-235.
140. Van Rompay KKA, Marthas ML, Ramos RA, Mandell CP, McGowan EK, Joye SM & Pedersen NC (1992) Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrobial Agents and Chemotherapy 36:2381-2386.
141. Van Rompay KKA, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, Tarara RP, Canfield DR, Telm S, Bischofberger N & Pedersen NC (1996) 9-[2-(phosphonylmethoxy) adenine therapy of established Simian immunodeficiency virus infection in infant rhesus macaques. Antimicrobial Agents and Chemotherapy 40:2586-2591.
142. Votruba I, Bernaerts R, Sakuma T, De Clercq E, Merta A, Rosenberg I & Holý A (1987) Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Molecular Pharmacology 32:524-529.
143. Wachsman M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A & Lietman PS (1996) Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Research 29:153-161.
144. Xiong X, Smith JL & Chen MS (1995) The consequence of incorporation of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine by human cytomegalovirus DNA polymerase on DNA elongation. Abstracts of the 8th International Conference on Antiviral Research, Santa Fe, New Mexico, USA, April 23-28 1995. Antiviral Research 26:A321.
145. Xiong X, Smith JL, Kim C, Huang E & Chen MS (1996) Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochemical Pharmacology 51:1563-1567.
146. Yokota T, Konno K, Chonan E, Mochizuki S, Kojima K, Shigeta S & De Clercq E (1990) Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrobial Agents and Chemotherapy 34:1326-1330.
147. Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S & De Clercq E (1991) Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrobial Agents and Chemotherapy 35:394-397.